GENMAB A/S's ticker is GMAB and the CUSIP is 372303206. A total of 205 filers reported holding GENMAB A/S in Q3 2021. The put-call ratio across all filers is 0.14 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $6 | -14.3% | 172 | 0.0% | 0.00% | – |
| Q2 2023 | $7 | +16.7% | 172 | 0.0% | 0.00% | – |
| Q1 2023 | $6 | -14.3% | 172 | 0.0% | 0.00% | – |
| Q4 2022 | $7 | -99.8% | 172 | +25.5% | 0.00% | – |
| Q3 2022 | $4,000 | 0.0% | 137 | 0.0% | 0.00% | – |
| Q2 2022 | $4,000 | -20.0% | 137 | 0.0% | 0.00% | – |
| Q1 2022 | $5,000 | 0.0% | 137 | 0.0% | 0.00% | – |
| Q4 2021 | $5,000 | -28.6% | 137 | -17.0% | 0.00% | – |
| Q3 2021 | $7,000 | +75.0% | 165 | +91.9% | 0.00% | – |
| Q2 2021 | $4,000 | +33.3% | 86 | 0.0% | 0.00% | – |
| Q1 2021 | $3,000 | 0.0% | 86 | 0.0% | 0.00% | – |
| Q4 2020 | $3,000 | -57.1% | 86 | -55.9% | 0.00% | – |
| Q3 2020 | $7,000 | +75.0% | 195 | +14.0% | 0.00% | – |
| Q2 2020 | $4,000 | 0.0% | 171 | 0.0% | 0.00% | – |
| Q1 2020 | $4,000 | 0.0% | 171 | 0.0% | 0.00% | – |
| Q4 2019 | $4,000 | – | 171 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aquilo Capital Management, LLC | 242,848 | $9,169,940 | 3.80% |
| Capricorn Fund Managers Ltd | 110,643 | $4,177,880 | 1.28% |
| Arlington Capital Management, Inc. | 35,591 | $1,343,916 | 1.26% |
| XY Capital Ltd | 76,884 | $2,903,140 | 1.13% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 88,000 | $3,322,880 | 0.93% |
| TORRAY INVESTMENT PARTNERS LLC | 110,807 | $4,184,072 | 0.75% |
| Hardman Johnston Global Advisors LLC | 585,139 | $22,094,849 | 0.72% |
| Yorktown Management & Research Co Inc | 16,600 | $626,816 | 0.68% |
| First Light Asset Management, LLC | 160,025 | $6,042,544 | 0.54% |
| MIRABELLA FINANCIAL SERVICES LLP | 28,260 | $2,505,855 | 0.38% |